Skip to main content
. Author manuscript; available in PMC: 2016 Jul 27.
Published in final edited form as: JAMA Neurol. 2013 Dec;70(12):1512–1519. doi: 10.1001/jamaneurol.2013.4013

Figure 1. Neurodegenerative Biomarkers in Cognitively Normal (NC) Cases and Patients With Alzheimer Disease (AD).

Figure 1

A, The template of cortical AD-affected regions. B and C, Percentage of individuals with normal and abnormal cortical thickness, fludeoxyglucose positron emission tomography (FDG-PET), and hippocampal volume (HV) and 0, 1, and more than 1 abnormal neurodegenerative biomarker for Berkley Aging Cohort (BAC) NC cases, Alzheimer's Disease Neuroimaging Initiative (ADNI) NC cases, and ADNI AD cases.